Immuneering
IMRX
35 hedge funds and large institutions have $6.84M invested in Immuneering in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
1.32% less ownership
Funds ownership: 13.86% → 12.53% (-1.3%)
17% less funds holding
Funds holding: 42 → 35 (-7)
27% less capital invested
Capital invested by funds: $9.32M → $6.84M (-$2.49M)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.43M |
| 2 |
SM
Southport Management
Wilson,
Wyoming
|
+$54.5K |
| 3 |
Jane Street
New York
|
+$37.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.7K |
| 5 |
Morgan Stanley
New York
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
-$390K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$196K |
| 3 |
Millennium Management
New York
|
-$145K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$145K |
| 5 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$128K |
IMRX Hedge Fund Activity: Q1 2025 in Review
35 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2025, worth a combined $6.84M — down 27% from $9.32M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IMRX and 5 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Marshall Wace, adding an estimated $1.43M. The largest seller was Rockefeller Capital Management, exiting entirely with an estimated $390K sold.
- 35 institutional investors held Immuneering (IMRX) as of Q1 2025, down from 42 in Q4 2024.
- Funds reported $6.84M of Immuneering stock for Q1 2025, down 27% quarter-over-quarter.
- 5 funds opened new Immuneering positions in Q1 2025 and 12 closed out, a net change of -7 holders.
- The largest Immuneering buyer in Q1 2025 was Marshall Wace, an estimated $1.43M added.
- The largest Immuneering seller in Q1 2025 was Rockefeller Capital Management, an estimated $390K sold.
Based on aggregated 13F filings for Q1 2025.